Novartis broadens cancer immune therapy pipeline with acquisition, pacts

ZURICH (Reuters) - Novartis has broadened its immuno-oncology pipeline with the acquisition of Admune Therapeutics and through licensing agreements with small drug developers Xoma and Palobiofarma.